Customers

Our current market for the HILOmet PhyzioType System is Connecticut-based and includes psychiatrists seeking assistance in the prescribing of antidepressant and stimulant to certain high-risk populations. The primary market for the beta launch of the PIMS PhyzioType System will be similarly targeted to assist psychiatrists in the prescribing of atypical antipsychotics (AAPs). The primary market for the beta launch of the SINM PhyzioType System will also be targeted to cardiologists and neurologists prescribing statin medications or treating their neuromyopathy symptoms.

We have begun to build an internal sales organization to market to regionally-based psychiatrists, cardiologists and neurologists as we expand the HILOmet PhyzioType business beyond Connecticut and the PIMS and SINM PhyzioType Systems beyond the beta stage. Consistent with current operations, all tests will be processed at our Laboratory of Personalized Health in Hartford, CT.

We intend to broaden our sales and marketing efforts, including partnerships with one or all of the following to help us establish broader, national adoption.

Physicians. Our internal sales and marketing efforts will initially be focused on marketing directly to medical specialists (psychiatrists, neurologists, cardiologists and endocrinologists) to update them with respect to the benefits of our PhyzioType Systems as a clinical tool which will enable them to proactively apply clinically-validated DNA-guided medicine to targeted patient populations with beneficial results. We believe our PhyzioType Systems can eventually evolve into mainstream medical care, particularly for certain high-risk patient populations. In order to achieve this, physicians must integrate our products into the standard of care for minimizing and managing common and potentially disabling drug side effects in their patients.

Diagnostics. To achieve broad distribution, PhyzioType Systems may be licensed to diagnostic companies for mass distribution and implementation worldwide on proprietary analytical platforms. Companies such as Roche, Abbott, Life Technologies, Siemens, or mid-tier diagnostic companies such as Illumina, Qiagen and Luminex with large stakes in laboratory medicine could be suitable strategic partners. Laboratory networks such as Quest and LabCorp at the national level, and hospital and regional reference laboratories are also candidates for licensing our medical management systems.

Healthcare Organizations, Insurers and Self-insured Employers. As the cost of healthcare continues to increase, there is an extraordinary need to establish innovative and effective mechanisms to rein in the skyrocketing cost of healthcare. We believe that our PhyzioType Systems can radically improve the prescription of drugs, reduce physician and hospital visits due to serious side effects and significantly reduce overall costs. In addition, our products could represent differentiating benefits as the companies compete for covered lives. We also plan to continue to conduct clinical studies with results published in peer-reviewed journals to increase medical demand and payor awareness.

Pharmacy Benefit Managers. This sector of the healthcare industry is adopting DNA-guided medicine as an innovation to their formulary management. Aggressive adoption of DNA-Guided Medicine may be spearheaded by competition for employer and insurance company contracts. Examples of early adopters in this category include Medco Health, Caremark and Express Scripts.

Disease Management. For this sector, vulnerable populations could serve as targets for deployment of the PhyzioType Systems. We expect the adult diabetic population to be a target for SINM and GLIM PhyzioType Systems. Adult diabetics would benefit from PhyzioType Systems to differentiate drug side effects from their disease comorbidities such as neuropathy and to benchmark the patient's innate risk of drug side effects in the implementation of therapeutic regimens incorporating multiple medications.